Cargando...
An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs)
Patients suffering from pancreatic neuroendocrine tumors (pNETs) are now candidates to receive novel approved drugs that have demonstrated benefit in disease control rate and delay the time taken for tumor progression in Phase III clinical trials; for example, sunitinib, everolimus and lanreotide. T...
Guardado en:
| Publicado en: | Rare Cancers Ther |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Springer Healthcare
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4837935/ https://ncbi.nlm.nih.gov/pubmed/27182476 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40487-015-0007-6 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|